TerminatedN/Apsilocybin
PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder
Sponsored by Usona Institute
NCT ID
NCT04353921
Target Enrollment
26 participants
Start Date
2020-06-30
Est. Completion
2022-10-18
About This Study
This is a Phase 2 double-blind, long-term observational follow-up study of participants from Study PSIL201. Participants providing informed consent were enrolled into this study and completed web surveys and telephone interviews conducted by one central site at the following time intervals: months 3 and 6 (± 7 days for each assessment) and months 10 and 12 (± 14 days for each assessment).
Conditions Studied
Interventions
- •No intervention will be administered as part of this study.
Eligibility
Age:21 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Enrollment and randomization in Study PSIL201 * Ability and willingness to provide informed consent prior to initiation of any study-related procedures Exclusion Criteria: * Inability or unwillingness to complete study procedures, including regular completion of web surveys and telephone interviews with study personnel
Study Locations (1)
Innovative Clinical Research, Inc. (formerly Segal Trials)
Lauderhill, Florida, United States